Acrivon Therapeutics, Inc. (ACRV) Income Statement
ACRV 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsACRV revenue and net income
ACRV growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ACRV quarterly EPS vs estimates
Acrivon Therapeutics beat the analyst EPS estimate in 7 of the last 8 quarters. Next report: November 12, 2026 (estimate $-0.45).
ACRV income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $1.4M | $1.0M | $536,000 | $1.1M | $832,000 | $13,000 |
| Gross profit | −$1.4M | −$1.0M | −$536,000 | −$1.1M | −$832,000 | −$13,000 |
| Research & development | $60.0M | $64.0M | $45.5M | $23.9M | $13.7M | $1.9M |
| Sales, general & admin | $24.1M | $25.2M | $21.2M | $8.7M | $2.5M | $1.3M |
| Total operating expenses | $82.8M | $88.2M | $66.7M | $32.7M | $16.2M | $3.2M |
| Operating income | −$84.1M | −$89.2M | −$67.2M | −$32.7M | −$16.2M | −$3.2M |
| Interest income | $6.5M | $9.2M | $7.0M | — | — | — |
| Interest expense | — | — | — | $1.5M | $59,000 | — |
| Income before taxes | −$77.9M | −$80.6M | −$60.4M | −$31.2M | −$16.2M | −$5.3M |
| Income taxes | — | — | $1 | −$1.5M | −$199,558 | −$193,297 |
| Net income | −$77.9M | −$80.6M | −$60.4M | −$29.7M | −$16.2M | −$5.3M |
| EBITDA | −$76.5M | −$79.5M | −$59.9M | −$32.3M | −$16.2M | −$5.3M |
| EPS (diluted) | −$2.02 | −$2.44 | −$2.73 | −$5.97 | −$1.26 | −$5.31 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $848,000 | $0 | $0 | $0 | $1.9M | $0 |
| Cost of revenue | — | $383,000 | −$911,000 | $300,000 | $300,000 | $311,000 | $303,000 | $300,000 | $200,000 | $224,000 | $149,000 | $331,000 |
| Gross profit | — | −$383,000 | $911,000 | −$300,000 | −$300,000 | −$311,000 | −$303,000 | −$300,000 | −$200,000 | −$224,000 | −$149,000 | −$331,000 |
| Research & development | $13.8M | $14.8M | $15.0M | $13.6M | $16.2M | $15.4M | $18.3M | $18.9M | $15.0M | $11.2M | $15.3M | $10.3M |
| Sales, general & admin | $4.8M | $4.7M | $5.4M | $6.0M | $6.5M | $6.2M | $6.3M | $6.3M | $6.4M | $6.2M | $5.6M | $5.9M |
| Total operating expenses | $18.7M | $19.5M | $21.0M | $19.7M | $22.3M | $21.4M | $24.7M | $25.1M | $21.4M | $17.4M | $20.9M | $16.1M |
| Operating income | −$18.7M | −$19.9M | −$20.1M | −$19.7M | −$22.6M | −$21.7M | −$25.0M | −$25.1M | −$21.4M | −$17.7M | −$21.1M | −$16.1M |
| Interest income | $860,000 | $989,000 | $1.2M | $1.5M | $1.7M | $2.0M | $2.4M | $2.7M | $2.7M | $1.4M | — | $1.8M |
| Interest expense | — | — | — | — | — | — | — | — | — | — | $1.6M | — |
| Income before taxes | −$18.0M | −$19.0M | −$19.0M | −$18.2M | −$21.0M | −$19.7M | −$22.8M | −$22.4M | −$18.8M | −$16.5M | −$19.3M | −$14.5M |
| Income taxes | — | — | — | — | — | — | −$180,724 | — | — | $180,724 | $1.8M | −$133,000 |
| Net income | −$18.0M | −$19.0M | −$19.0M | −$18.2M | −$21.0M | −$19.7M | −$22.8M | −$22.4M | −$18.8M | −$16.5M | −$19.3M | −$14.5M |
| EBITDA | −$17.6M | −$18.7M | −$24.8M | −$17.9M | −$20.7M | −$19.4M | −$22.5M | −$22.2M | −$18.6M | −$16.3M | −$19.1M | −$14.3M |
| EPS (diluted) | −$0.43 | −$0.49 | −$0.49 | −$0.47 | −$0.55 | −$0.51 | −$0.60 | −$0.59 | −$0.52 | −$0.73 | −$0.86 | −$0.66 |
| Gross margin | — | — | — | — | — | — | −35.7% | — | — | — | −7.9% | — |
| Operating margin | — | — | — | — | — | — | −2,942.7% | — | — | — | −1,117.5% | — |
| Net margin | — | — | — | — | — | — | −2,692.3% | — | — | — | −1,021.9% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ACRV's financial statements (latest annual report filed March 19, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ACRV financial results
Acrivon Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $77.9 million. Diluted earnings per share came to −$2.02.
See the ACRV stock overview for the latest quote and news, or the ACRV chart for price history and technical indicators.
ACRV income statement FAQ
Does Acrivon Therapeutics have revenue?
Acrivon Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Acrivon Therapeutics profitable?
No. Acrivon Therapeutics reported a net loss of $77.9 million in fiscal 2025.
How much does Acrivon Therapeutics spend on research and development?
Acrivon Therapeutics spent $60.0 million on research and development in fiscal 2025.
What are Acrivon Therapeutics's earnings per share?
Acrivon Therapeutics earned $-2.02 per diluted share in fiscal 2025, compared with $-2.44 a year earlier.
When will Acrivon Therapeutics report its next earnings?
Acrivon Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 12, 2026.
When does Acrivon Therapeutics's fiscal year end?
Acrivon Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 19, 2026.